PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Bioresorbable Scaffolds Carry Higher Ischemic Risk Than Drug-Eluting Stents Through Five Years

bioresorbable vascular scaffolddrug-eluting stentAbsorbMagmariseverolimus-eluting stentcoronary artery diseasepercutaneous coronary interventionmeta-analysistrial sequential analysisstent thrombosisdual antiplatelet therapy Cardiology

Background Information

Drug-eluting stents outperform bioresorbable scaffolds in coronary artery safety.

Understanding the comparative efficacy of bioresorbable vascular scaffolds (BVS) versus drug-eluting stents (DES) is crucial for improving outcomes in coronary artery disease. BVS showed a higher risk of adverse events at one year, including myocardial infarction (MI) and thrombosis, compared to DES. The evidence suggests BVS presents higher ischemic risks with no long-term survival benefit, indicating DES should remain the standard revascularization strategy. DES outperforms BVS in safety and efficacy for coronary artery disease revascularization.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Yu Y, Shang K, Jiao Y, Chang S, Li Y, Song G, Yin C

Citation: Yu Y, Shang K, Jiao Y, et al. Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. Reviews in cardiovascular medicine. 2026;27(10):51636. doi:10.31083/RCM51636

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.